Eli Lilly Reports 39% Revenue Growth Driven by Increased Sales Volume
Eli Lilly (LLY) reported a significant third-quarter revenue increase of 39%, reaching approximately $24.4 billion. This growth was primarily driven by a 53% surge in sales volume, which successfully offset a 15% decline in realized prices resulting from lower drug pricing strategies intended to expand patient access. The company's weight-loss and diabetes drugs, Mounjaro and Zepbound, accounted for roughly two-thirds of total revenue. Despite the price reductions, gross margins expanded to 83.9% due to falling production costs per dose and a shift toward higher-margin products. Consequently, management raised its full-year revenue guidance by $5.5 billion at the midpoint.
Topics: earnings report guidance increase pharmaceuticals revenue growth
Read the full article at Motley Fool
Part of the story Eli Lilly Demonstrates Revenue Growth Beyond GLP-1 Weight Loss Drugs (10 articles)